Inhibitor Therapeutics (Inhibitor Therapeutics) Earnings per Share (Diluted) : $-0.02 (TTM As of Dec. 2023)

Inhibitor Therapeutics Earnings per Share (Diluted) Chart

Inhibitor Therapeutics Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Earnings per Share (Diluted)		Get a 7-Day Free Trial					-0.01	-	-	0.03	-0.02

Inhibitor Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Earnings per Share (Diluted)	Get a 7-Day Free Trial															0.03	-	-	-	-0.01

Competitive Comparison of Inhibitor Therapeutics's Earnings per Share (Diluted)

For the Biotechnology subindustry, Inhibitor Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inhibitor Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibitor Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Inhibitor Therapeutics's PE Ratio falls into.

Inhibitor Therapeutics Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Inhibitor Therapeutics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Inhibitor Therapeutics's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Inhibitor Therapeutics  (OTCPK:INTI) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Inhibitor Therapeutics Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Inhibitor Therapeutics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibitor Therapeutics (Inhibitor Therapeutics) Business Description